International Assets Investment Management LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 11,001 shares of the biopharmaceutical company’s stock, valued at approximately $30,260,000.
A number of other large investors also recently added to or reduced their stakes in the business. Lecap Asset Management Ltd. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $669,000. Signaturefd LLC raised its position in Alnylam Pharmaceuticals by 34.1% in the 3rd quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 471 shares during the period. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 161 shares during the period. Essex LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $217,000. Finally, Friedenthal Financial purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $51,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Price Performance
NASDAQ:ALNY opened at $286.91 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s 50-day simple moving average is $274.68 and its 200 day simple moving average is $223.34. The firm has a market capitalization of $36.29 billion, a P/E ratio of -107.06 and a beta of 0.39.
Insiders Place Their Bets
In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,398 shares of company stock valued at $13,595,460. Insiders own 1.50% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have issued reports on ALNY shares. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. Scotiabank started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $305.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Finally, Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $290.86.
View Our Latest Stock Analysis on Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
See Also
- Five stocks we like better than Alnylam Pharmaceuticals
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Inflation Risk Rising, Key Trades Investors Are Making Now
- The 3 Best Fintech Stocks to Buy Now
- 3 Oil Stocks to Watch Before Earnings Come Out
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.